Fact Sheet: President Donald J. Trump Announces Deal with Regeneron to Bring Most-Favored-Nation Pricing to American Patients

4/23/2026

Fact Sheets

View Original

Action Summary

MFN Pricing Agreement: President Trump announced the 17th deal with Regeneron to implement most-favored-nation pricing on new innovative medicines, ensuring U.S. drug prices match the lowest prices in other developed nations.
Medicaid Savings and Patient Benefits: Every State Medicaid program will benefit from MFN pricing, leading to hundreds of millions in savings and significant price reductions, such as lowering Praluent from $537 to $225 through TrumpRx.
International Revenue Repatriation: Regeneron must repatriate increased foreign revenue from existing products as a result of the administration’s America First trade policies, preventing other nations from free-riding on U.S. innovation.
Expansion of MFN Deals: This is the 17th agreement covering major pharmaceutical manufacturers representing 86% of the branded drug market, further rebalancing international drug pricing for American patients.
Breakthrough Rare Disease Treatment: Regeneron’s new gene therapy, Otarmeni, for a rare genetic deafness, will be provided at no cost, expedited through the FDA’s National Priority Voucher Program.
U.S. Investment in R&D and Manufacturing: Regeneron commits to investing $27 billion in U.S. research, development, and manufacturing by 2029, more than doubling its domestic manufacturing capacity.
Historical Continuity: The agreement builds on previous executive actions and announcements, including the signing of an EO on delivering MFN pricing, subsequent letters to 17 leading manufacturers, the launch of TrumpRx.gov, and several key international and domestic agreements over the past year.

Risks & Considerations

The Executive Order promoting Most-Favored-Nation (MFN) pricing could lead to significant changes in how pharmaceutical pricing is structured in the U.S. This may create competitive pressures for drug manufacturers, potentially impacting their investment in research and development.
There is a risk that the MFN pricing model may not sufficiently address the complexities of healthcare access and affordability. While it aims to lower prices, it could inadvertently limit the availability of certain medications if manufacturers choose to withdraw products from the market due to reduced profit margins.
Vanderbilt University may face challenges in securing partnerships with pharmaceutical companies for research and clinical trials, as these companies may reallocate resources in response to new pricing pressures.
The implementation of MFN pricing may require adjustments in the University’s healthcare plans and policies, especially if drug prices fluctuate significantly as a result of these changes.

Impacted Programs

Vanderbilt University Medical Center may need to adapt its pricing and procurement strategies as drug costs change, ensuring that patient care remains affordable while maintaining high-quality services.
The School of Medicine could experience shifts in research funding and collaborations with pharmaceutical companies, leading to potential opportunities or challenges in securing grants for innovative research.
The Office of Health Affairs may need to engage in advocacy or policy discussions to ensure that the needs of patients and healthcare providers are effectively represented in the evolving drug pricing landscape.
Programs focused on healthcare equity and access might need to reevaluate their strategies to ensure that price reductions benefit all patients, particularly vulnerable populations.

Financial Impact

The MFN pricing initiative could result in significant savings for patients, but it may also disrupt existing funding models for healthcare institutions, including Vanderbilt, as drug revenue streams fluctuate.
Changes in drug pricing may affect the financial viability of certain clinical programs, leading to potential budget reallocations or cuts in services if manufacturers reduce their product offerings.
Opportunities may arise for Vanderbilt to engage in new partnerships with companies focusing on innovative therapies and patient care solutions, particularly in light of the substantial investment Regeneron is making in U.S. research and development.
Vanderbilt may need to adjust its financial aid and patient assistance programs to accommodate shifts in drug availability and pricing structures.

Relevance Score: 4 (The order presents a need for potential major changes or transformations of programs.)

Key Actions

The Vanderbilt University Medical Center (VUMC) should prepare for potential budgetary adjustments due to federal policy changes impacting NIH research grants. This includes developing strategies to mitigate a projected $250 million budget cut and securing alternative funding sources to maintain research initiatives.
The Office of Federal Relations should engage with policymakers to advocate for the preservation of NIH funding levels, emphasizing the importance of continued investment in medical research and education, particularly in light of proposed budget reductions affecting federal grants.
Vanderbilt’s Center for Child and Family Policy should explore the implications of the MFN pricing strategy on healthcare access and affordability for students and their families, and develop outreach programs to educate the community about new drug pricing models and available treatments.
The Department of Health Policy at Vanderbilt should analyze the impact of the new MFN pricing agreements on public health outcomes in Tennessee and develop recommendations for state health policy adjustments that align with federal initiatives.
The Vanderbilt Law School should consider incorporating courses related to healthcare law and policy that reflect the changing landscape of pharmaceutical pricing and access, preparing students for careers in this increasingly relevant field.

Opportunities

The MFN pricing agreements present an opportunity for Vanderbilt’s Health Policy Research Center to lead studies assessing the efficacy of these pricing strategies in improving healthcare access and outcomes, positioning the university as a thought leader in health economics.
Vanderbilt can leverage the announcement of Regeneron’s new gene therapy to create partnerships with local healthcare providers to facilitate access to innovative treatments for rare diseases, enhancing its community engagement and service.
The significant investment by Regeneron in U.S. research and manufacturing offers a chance for Vanderbilt to collaborate on cutting-edge research projects, potentially leading to joint ventures that could enhance its research capabilities and attract additional funding.
The announcement of cost reductions for medications through TrumpRx can be an opportunity for Vanderbilt’s Pharmacy School to develop educational programs focused on pharmacoeconomics and the implications of pricing strategies in healthcare.
The university can utilize this momentum to host symposiums and workshops focused on healthcare policy and drug pricing, bringing together stakeholders from academia, industry, and government to discuss innovations and solutions in healthcare access.

Relevance Score: 4 (The actions and opportunities outlined are significant due to the potential for major process changes required in response to federal policy shifts impacting healthcare access and funding.)

Average Relevance Score: 3.4

Timeline for Implementation

May 12, 2025: Executive Order signed directing actions to align U.S. drug prices with MFN pricing.
July 31, 2025: Letters sent to 17 leading pharmaceutical manufacturers outlining the steps to reduce U.S. prescription drug prices.
September 30, 2025: First MFN pricing agreement (with Pfizer) announced, marking an early milestone for these directives.
December 1, 2025: Announcement of an agreement with the U.K. to adjust drug pricing, ensuring foreign markets pay their fair share.
December 19, 2025: Nine additional major agreements with pharmaceutical companies announced.
February 5, 2026: Launch of TrumpRx.gov, enabling patients to access drugs at MFN prices.
By 2029: Regeneron commits to invest $27 billion in U.S. research, development, and manufacturing.

The shortest timeline is the 61-day period from the issuance of directive letters on July 31, 2025 to the implementation milestone on September 30, 2025.

Relevance Score: 3

Impacted Government Organizations

State Medicaid Programs (administered by HHS): The agreement specifically provides every state Medicaid program access to MFN drug prices, affecting how these programs manage and negotiate prescription drug costs for vulnerable populations.
Food and Drug Administration (FDA): The FDA, through its Commissioner’s National Priority Voucher Program, expedited the review and approval process for Regeneron’s new gene therapy for a rare genetic deafness, impacting its regulatory role.
Office of the United States Trade Representative (USTR): The USTR is involved as the agreement and previous measures, such as the deal with the United Kingdom, link international trade policies to domestic drug pricing and market fairness.
Department of Commerce: This department played a role in prior international agreements that affect net prescription drug prices abroad, thereby influencing domestic pricing strategies through trade policies.
Department of Health and Human Services (HHS): HHS is implicated both through its oversight of Medicaid and broader health policy implementations concerning drug pricing reforms under the MFN framework.

Relevance Score: 2 (Between 3 and 5 agencies are directly impacted by the directive.)

Responsible Officials

Office of the United States Trade Representative – Charged with leading the international trade negotiations that enforce MFN pricing measures, as evidenced by their role in the U.K. agreement announcement.
Department of Commerce – Responsible for executing trade policy aspects and supporting the implementation of agreements that adjust foreign pricing dynamics.
Department of Health and Human Services – Tasked with overseeing the broad execution of drug pricing policies to ensure patient access and affordability.
FDA Commissioner – Implemented the expedited review process under the National Priority Voucher Program, facilitating rapid approval of new therapies such as the gene therapy for Otarmeni.

Relevance Score: 4 (Directives affect senior agency officials, including agency heads, in key government departments.)